New treatment options for myelodysplastic syndrome and acute myeloid leukemia
Official title: A novel approach for treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)
Funded at Avantgen, INC. · NIH-10920336 · Data updated 2026-11-12
This study is exploring new treatment options for people with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) by looking at their genetic makeup and developing targeted therapies that could help improve their health.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Avantgen, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | September 9, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,398,552 |
| NIH project number | 1R44CA291331-01 |
| Project ID | NIH-10920336 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients diagnosed with myelodysplastic syndrome or acute myeloid leukemia, particularly those who have not responded well to existing therapies.
✕Less likely to help
Patients with early-stage MDS who are asymptomatic and do not require treatment may not benefit from this research.
What this research studies
This research investigates innovative treatment strategies for patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It aims to develop targeted therapies that could improve outcomes for patients who currently have limited treatment options. The approach focuses on understanding the genetic mutations associated with these conditions and utilizing advanced biomanufacturing techniques to create effective therapies. Patients may be involved in clinical trials to evaluate the safety and efficacy of these new treatments.
Why it matters
Potential benefit: If successful, this research could provide more effective treatment options and improve survival rates for patients with MDS and AML.
How similar studies have gone: Other research has shown promise in developing targeted therapies for AML, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Avantgen, INC.
San Diego, United States Active
Researchers
- Principal investigator: Fan, Xiaomin — Avantgen, INC.
- Study coordinator: Fan, Xiaomin
Related research
Other NIH-funded projects on the same topics.
-
New treatment approach for myelodysplastic syndrome and acute myeloid leukemia
This project aims to develop a new antibody-based therapy to help people with MDS or AML, especially older or frail patients who cannot tolerate high-dose chemotherapy.
-
Acute Myeloid Leukemia: Improving Targeted Therapies through Genetically Defined PDX Models
Researchers are using patient-like leukemia models to develop therapies that target specific genetic features of AML to improve survival.
-
A broader genomic risk picture to guide AML treatment
AIM to refine how genetic information guides treatment decisions for adults with acute myeloid leukemia by looking at how inherited and recurrent mutations affect risk.
-
RNA Polymerase II as a Therapeutic Target in AML with RAS Activation
This project explores a new way to treat a common type of blood cancer (AML) by blocking a key machinery (RNA Polymerase II) that cancer cells use when the RAS signaling pathway is overactive.
-
SHP2 and BCL2 inhibitors together for AML growth and resistance
A patient-focused look at whether combining SHP2 inhibitors with a BCL2 inhibitor can slow or stop AML, especially in people whose disease has FLT3 or KIT mutations.
-
Targeting RNA polymerase II in AML with RAS pathway activation
This project tests drugs that block RNA polymerase II to help people whose acute myeloid leukemia has RAS pathway activation and is resistant to FLT3 inhibitors.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.